failed_experiment.db
← Back to browse

Medicine› Neurology› Parkinson's Disease Mechanisms and Treatments

Parkinson's disease — LRRK2 (wild-type and G2019S)

Submitted 2026-10-23

Field: Medicine › NeurologyType: No effect foundArea: parkinson's diseaseTarget: LRRK2 (wild-type and G2019S)Stage: preclinical

Hypothesis

High levels of LRRK2, especially the G2019S mutant that causes inherited Parkinson's disease, would cause or worsen alpha-synuclein disease in mouse brain neurons.

What failed

High LRRK2 left alpha-synuclein and Tau levels unchanged and did not worsen alpha-synuclein disease in mice that also made high alpha-synuclein. In some lines, high LRRK2 improved motor skills.

Broken assumption

Raising LRRK2 levels in neurons is enough to drive or worsen alpha-synuclein disease.

Why

The abstract does not give a cause. Many neurons tolerate high LRRK2 well.

From the published paper: Herzig et al. PLoS ONE, 2012. ↗CC BY

Research ideas from this failure

Unvetted lead — read the papers

New hypotheses this failure suggests, each with a crucial experiment, a rival explanation of the original result, and the papers it rests on. Written by AI from paper titles and abstracts found on OpenAlex (and Europe PMC, for life and health sciences).

Related failures (5)

Matched on shared genes, mechanisms and ways of failing as well as wording. Each shows why it matched — treat these as leads rather than verdicts.

Links in published research

Where this experiment's genes are known to matter outside its own research area, and the papers behind those links. Sources: Open Targets Platform and Europe PMC.